ADVANCED SOLID TUMOR

This early-phase study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors (cancers that have spread). The drug is designed to target a protein (Claudin 6) found on some cancer cells. The main goals are to find a safe dose and understand side effects. T…

This early-phase study tests a new cancer treatment called FT825 (also known as ONO-8250) in people with advanced solid tumors that have HER2 or other markers. The therapy uses pre-made immune cells (CAR T-cells) that are designed to attack cancer, and may be combined with antibo…

This early-phase study tests a new drug called M3554 in people with advanced solid tumors, specifically soft tissue sarcoma and a type of brain cancer (glioblastoma). The main goals are to find the safest dose and check for side effects. About 52 participants will receive the dru…

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Researchers will also watch for a…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…

This early-stage study tests a new drug called M0324 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells and boost the immune system. Researchers will test M0324 alone, with another immunotherapy (pembro…

This study tests a new drug called YL242, given alone or with other treatments, in people with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 adults will take part across multiple sites.

This early-phase study tests a new drug called YL217 in about 220 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how the dr…

This early-phase study tests a new experimental drug, ASKC202, alone or with another drug (ASK120067), in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink t…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This study tests a new drug, CLIO-8221, in about 306 adults whose solid tumors have spread or cannot be removed and who have already tried other treatments. The first part finds a safe dose; the second part checks if the drug shrinks tumors. The goal is to control the disease, no…

This study tests a new drug, OBI-902, in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: first, finding a safe dose; second, checking how well it works in certain cancers; and third, picking the best dose for larger stu…

This study tests an experimental drug called BNT326, alone or with other cancer treatments, in people with advanced solid tumors that have spread or come back. The goal is to find the safest dose and see if it shrinks tumors. About 980 adults will take part.

This study tests a treatment using immune cells called TILs, taken from a patient's own tumor, grown in a lab, and given back through an IV. It is for people with advanced solid tumors who have not responded to standard treatments. The goal is to see if this therapy is safe and c…

This early-phase study tests a new drug called JMT106 in about 200 adults with advanced solid tumors (including lung and liver cancer) who have run out of standard options. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants…

This early-phase study tests a new drug called GTB-5550 in people with advanced solid tumors that no longer respond to standard treatments. The drug is designed to connect natural killer cells to cancer cells, helping the immune system attack the tumor. About 175 adults aged 18 a…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…

This early-phase study tests a new drug called lunresertib, alone or with other drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 46…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if STK-012 is safe and can shrink tumors better than cur…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or relapsed acute myeloid leukemia (AML). The main goals are to check safety and find the best dose. About 260 adults will take part acr…

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drugs can shrink …

This early-phase trial tests an experimental drug called LP-284 in about 110 adults whose lymphomas or solid tumors have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. Researchers will also monito…

This early-phase study tests whether giving targeted radiation to up to 10 tumor spots can improve the effects of immunotherapy in people with advanced solid tumors that have spread to 3-10 places in the body. About 28 adults will receive the combined treatment, and researchers w…

This study tests a new drug called ZGGS18 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand how the drug behaves in the body. About 222 participants will take part in this early-phase trial.

This early-phase study tests a new drug called LM-2417, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. A…

This early-stage study tests a new drug (CHS-114) combined with an immunotherapy (toripalimab) in people with advanced or metastatic solid tumors that have not responded to prior treatments. The main goal is to check safety and see if the combination can shrink tumors. About 154 …

This study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…

This early-stage study tests a new drug, BNT317, for the first time in people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to check the drug's safety and find the best dose. About 39 participants will rece…

This early-stage study tests an experimental pill called BB102 in people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (FGFR4) that some cancers need to grow. The main goals are to check safety, find the best …

This study tests a new drug, EP0031, in 265 adults with advanced cancers (like lung cancer) that have a specific RET gene change. The goal is to see if the drug is safe and shrinks tumors. Participants take the drug by mouth, and doctors monitor side effects and how well it works…

This early-phase study tests an investigational drug called ADCE-T02 in people with advanced solid tumors that have not responded to prior treatments. The drug is designed to seek out and attack cancer cells by targeting a protein called tissue factor. The main goals are to find …

This early-phase study tests a new drug called XB628 in about 75 people with advanced solid tumors that have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to find a safe dos…

This study tests two experimental drugs, QLP2117 and QL2107, given together to people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control the tumors. About 149 adults will take par…

This early-phase study tests a new drug called AN4005 in about 31 adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants will r…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (like lung, head and neck, pancreatic, or kidney cancer). The drug is designed to help the immune system fight cancer by targeting a protein called CD73 and delivering a modified immune s…

This early-phase study tests an experimental drug called GS-5319 in adults with advanced solid tumors that have a specific gene deletion (MTAP). The goal is to find a safe dose and see how well people tolerate the drug. About 178 participants whose cancer has worsened after stand…

This early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific AKT1 E17K gene change. The main goal is to check the drug's safety and find the right dose. Participants must have…

This study tests a new drug called QLC5508, given together with other anti-cancer medicines, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 444 adul…

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This early-phase study tests the safety of a drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. About 28 participants will receive the drug to see how their bodies process it and what side effects occur. The goal is to find the…

This study tests a new drug called IPN01195 in adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 85 people will take part in two phases: first to check safe…

This early-phase study tests a new drug called AM-928, given as an IV infusion, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control tumor growth…

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This study is the first to test AVZO-023, an oral drug that blocks a protein called CDK4, in people with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if it can shrink tumors. About 380 adults with HR+/HER2- brea…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study is testing an experimental drug called BG-75098, alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 105 participants will…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-stage study tests a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurab…

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The goal is to see if the drug is safe and how the body processes it. About 234 adults will take part, receiving the…

This early-phase study tests a new drug called WJB001 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard care. The goal is to find safe doses and see if the combinations can shrink tumors. About 86 adults will participa…

This study tests a modified salmonella bacteria (SGN1) injected directly into tumors in people with advanced solid cancers that haven't responded to standard treatments. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine…

This study tests an experimental drug called CX-5461 in people with advanced solid tumors (pancreas, prostate, breast, or ovary) that have BRCA2 or PALB2 gene mutations. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 52 participa…

This early-phase study tests an investigational drug called HCB301 in adults with advanced solid tumors or classical Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumo…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…

This early-stage trial tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that haven't responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This early-phase study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and can shrink tumors, either alone or with other cancer treatments. About 340 adults whose cancer has …

This study tests an experimental drug called HH2853 in people with certain blood cancers (non-Hodgkin's lymphomas) or advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 254 adults will…

This early-phase study tests a new drug called OMTX705, either alone or with an immunotherapy drug, in people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. About 150 adults with cert…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target two cancer-related proteins (EGFR and MET) and deliver a chemotherapy-like payload directly to cancer cells. Th…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study tests an experimental drug called HY05350 in people with advanced solid tumors that have a specific protein called MSLN. The goal is to find safe doses and see if the drug can shrink tumors. About 262 adults who have not responded to standard treatments will take part.

This early-stage trial tests a new drug called PTT-4256 in 30 adults with advanced solid tumors that have spread. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors.

This study tests an experimental drug called JAB-23E73 in people with advanced solid tumors that have a specific genetic change (KRAS mutation or amplification). The goal is to check the drug's safety and how well it works at shrinking tumors. About 334 participants will take the…

This early-stage study tests a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About …

This early-phase study tests a new oral gel called TRX-920 in 30 people with advanced solid tumors that no longer respond to standard treatments. The gel contains an active anti-cancer drug (SN38) and aims to shrink tumors with fewer side effects than current IV chemotherapy. The…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread. The drug is designed to block two cancer pathways (PD-1 and VEGF) at once. The main goals are to find the safest dose and check for side effects. About 387 adults will take part in th…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This early-phase study tests a new drug called NXP900 in about 140 adults with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors…

This early-stage study tests a new drug called JZP898, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This study tests an experimental drug called BG-75202, alone or with other treatments, in people with advanced breast cancer or other solid tumors that have stopped responding to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can s…

This study is testing a modified salmonella bacteria (SGN1) designed to grow inside tumors and cut off their food supply, potentially shrinking or slowing them. It is for people with advanced solid tumors that have not responded to other treatments. The trial will first check saf…

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe and recommended dose. About 217 …

This study tests whether combining two targeted drugs, pemigatinib and afatinib, is safe and works against advanced solid tumors that have certain FGFR gene changes. About 70 adults whose cancers have not responded to standard treatments will take part. The goal is to find the be…

This early-phase study tests a new drug called YL201, alone or with other cancer treatments, in about 312 adults with advanced solid tumors that have stopped responding to standard therapies. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two…

This early-phase study tests a new drug called IL12-L19L19 in 80 adults with advanced or metastatic solid tumors that have not responded to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug might shrink tumors. The drug is design…

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors, including certain gynecological and genitourinary cancers. The goal is to see if the drug can shrink tumors or control the disease. About 200 adults who have alre…

This study tests an experimental drug called ART6043, taken as a pill, for people with advanced or metastatic solid tumors. The drug is given alone or with another cancer medicine (olaparib). The goal is to see if it is safe and can slow tumor growth. About 181 adults will take p…

This early-stage study tests a combination of two drugs (valemetostat tosylate and a DXd antibody-drug conjugate) in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety and find the right dose, and to see if the combin…

This early-stage study tests a new drug called LM-24C5 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 49 adults will take part in this open-labe…

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This early-stage study tests a new drug called STX-001, given as an injection directly into tumors, for people with advanced solid tumors that have not responded to other treatments. The study will also test STX-001 combined with the immunotherapy drug pembrolizumab. The main goa…

This early-stage study tests a new drug called AXT-1003 in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for side effect…

This study tests a new drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer. The drug targets a specific genetic change (RET mutation or fusion) that helps some cancers grow. The study has two parts: first finding the…

This study tests a genetically modified bacteria (T3P-Y058-739) in 100 adults with advanced solid tumors that have no standard cure. The goal is to find a safe dose and see if the bacteria, given alone or with an immunotherapy drug, can shrink tumors or slow their growth.

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. The trial includes up to 48 adults with advanced solid tumors that have not responded to standard treatments. Researchers are checking safety, the best do…

This early-phase study tests a new drug called PM54 in about 125 adults with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose by watching for side effects; the second part checks if the drug can shrink tumors. The goal is …

This early-phase study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic markers (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This study tests an experimental pill, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein that helps cancer cells divide. The trial has two parts: first finding a safe dose, then checking if it shrinks …

This early-stage study tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 196 adults aged 18 to 75 will t…

This study tests a new medicine called SNV1521 in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check if it is safe, find the best dose, and see if it can be combined with other cancer treatments. About 400 participants will take p…

This early-phase study tests an experimental drug called ISM6331 in people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 10…

This study is testing a new drug, PEEL-224, for the first time in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. About 65 participants will take part in this ea…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug aims to block a protein (CD73) that helps tumors hide from the immune system. The trial first finds the safest dose alone, then tests it with chemotherapy and an…

This study tests a new drug called LBL-024 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18-80 will take part.

This study tests a new treatment plan for people with locally advanced rectal cancer. Participants first get a short course of radiation plus a drug called IL-2, then receive chemotherapy and two immunotherapy drugs. The goal is to see if this combination can make the cancer comp…

This early-stage study tests a new drug, ONC-841, in about 72 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug by IV, either alone or with standard trea…

This study tests a new drug called IPN01203 in adults with advanced solid tumors that have spread and no longer respond to standard immune therapies. The goal is to find a safe and effective dose and see if the drug can slow or stop tumor growth. About 102 participants will recei…

This early-phase study tests a new drug called BG-C9074, designed to seek out and attack cancer cells while sparing healthy ones. It is for people with advanced solid tumors that have not responded to standard treatments. The study will test the drug alone and in combination with…

This study is for adults with advanced solid tumors who have run out of standard treatments. It tests a new drug called BNT3212, either alone or with another drug (pumitamig), to see if it is safe and can shrink tumors. The trial is in early phases (1 and 2) and will enroll about…

This early-phase study tests a new drug called denikitug, alone or with another cancer drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tum…

This study tests a new drug, XTX301, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 358 participants will take part in this early-phase trial across multiple centers…

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …

This early-phase study tests a new drug called INI-4001, alone or with standard immunotherapy, in people with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 50 adults with various cancers that cannot be cured with cu…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This early-stage study tests a new drug called ERX-315 in people with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that no longer respond to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. About 15 …

This study tests a new drug, ifinatamab deruxtecan, in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well the …

This study tests a new drug called LM-108, given with or without another drug (penpulimab) plus chemotherapy, in people with advanced solid tumors that have not responded to other treatments. The goal is to find the best dose and see if the combination can shrink tumors or slow t…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard treatments. The drug is given both into a vein and directly into the tumor to see if it can shrink or contro…

This study tests a new drug called DB-1310 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Up to 1,000 adults will take part in this early-phase trial.

This study tests a new drug called IMP1734 in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors or slow their growth. About 156 adults with certain types of breast, ovarian, or prostate c…

This early-stage study tests a new injection called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants will be closely monito…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This early-phase study tests a new oral drug, SW-682, in adults with advanced solid tumors that have not responded to standard treatments. The study focuses on cancers with specific genetic changes in the Hippo pathway. The goal is to find a safe dose and see if the drug can shri…

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This early-phase study tests a new drug called HCB101 in adults with advanced solid tumors or non-Hodgkin lymphoma that hasn't responded to standard treatments. The main goals are to check safety and find the right dose. About 80 participants will receive the drug through an IV t…

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This early-stage study tests a new drug called MBS8(1V270) in about 106 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumo…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-stage study tests a new drug, ARC101, in about 70 people with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the drug shrinks tumors…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain types of breast cancer, head and neck cancer, or …

This early-stage study tests a new drug called BG-T187, which is designed to attach to two cancer-related targets (EGFR and MET) to attack tumor cells. About 87 adults with advanced solid tumors that have not responded to prior treatments will receive the drug alone or with other…

This early-stage study tests a new oral drug called APR-1051 in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose, while also looking for signs that it might shrink tumors. Pa…

This early-phase study tests a new experimental drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The main goals are to check the drug's safety, find the best dose, and see if …

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…

This early-stage study tests a new drug called ABL103 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 96 participants will receive the drug intravenously, and re…

This study tests a new drug called SHR-4375 combined with other cancer treatments in 198 adults with advanced solid tumors that have not responded to standard care. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth. Participants must…

This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…

This early-phase study tests a new drug called BG-C137 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cells with a specific marker (FGFR2b). The main goals are to check safety…

This early-phase study tests a new imaging drug (89Zr-DFO-REGN5054) that may help doctors see immune cells inside tumors using PET scans. About 50 adults with advanced solid cancers who are also receiving the immunotherapy cemiplimab will take part. The main goal is to check safe…

This early-phase study is testing whether adding metformin (a common diabetes medicine) to standard chemotherapy or immunotherapy is safe for people with advanced solid tumors. About 60 adults will take metformin alone for two weeks, then continue it alongside their regular cance…

This study tests whether a special clinic that checks your genes and medications can lower the chance of harmful drug interactions. About 1,300 adults with cancer or mental health conditions who take multiple medications will participate. Researchers will compare how well the cli…

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.

This study tests a new radioactive tracer called 64Cu-GRIP B, which attaches to a protein (granzyme B) made by immune cells. By using PET scans, doctors hope to see which tumors are responding to immunotherapy. The trial involves about 91 adults with advanced prostate, kidney, or…

This study looks at the genetic makeup of tumors from 40 adults with advanced solid tumors or lymphoma. The goal is to use this information to better match patients with early phase clinical trials. Participants provide a tissue sample from a past surgery or biopsy, but no new tr…